H

Hemab Therapeutics

22 employees

Hemab is a clinical-stage biotech company developing prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders.

Basic info

Industry

biotechnology research

Sectors

Biotechnology
Biotech
Pharmaceutical
Life Science

Date founded

2019

Funding rounds raised

Total raised

$135M

from 9 investors over 9 rounds

H

Hemab Therapeutics raised $135M on February 21, 2023

Investors: RA Capital Management, L.P., Novo Holdings, The Invus Group, LD INVEST and HealthCap

H

Hemab Therapeutics raised $55M on July 22, 2021

Investors: HealthCap, Novo Holdings and RA Capital Management, L.P.

H

Hemab Therapeutics raised undisclosed on December 14, 2020

Investors: Novo Holdings

FAQ